Volm M, Wayss K, Mattern J, Kleckow M, Vogt-Moykopf I
Dtsch Med Wochenschr. 1978 Aug 11;103(32):1266-70. doi: 10.1055/s-0028-1129244.
In a pilot study of 40 patients with inoperable bronchiogenic carcinomas the results of clinical therapy were compared with those of in vitro tests by measuring the effects of cytostatic agents on the incorporation of precursors into DNA and RNA in tumour cells incubated in vitro for short periods. Tumour cells that showed little inhibition by the cytostatic agents in vitro (less than 30% inhibition at a concentration of 10(-2) mg/ml adriamycin) came from patients who responded poorly to cytostatic therapy. On the other hand, tumour cells that were strongly inhibited in vitro (greater than 30% inhibition) came from tumours which proved to be sensitive to the chemotherapy given to the patient. A strong correlation existed between the inhibition of uridine incorporation by the tumour cells in vitro by adriamycin and the responses of the tumour to clinical therapy even when combination-therapy was given without adriamycin. There was also a significant correlation between the inhibiting effect of adriamycin in vitro and the survival time of the tumour patients.
在一项针对40例无法手术的支气管源性癌患者的初步研究中,通过测量细胞抑制剂对短期体外培养的肿瘤细胞中前体掺入DNA和RNA的影响,将临床治疗结果与体外试验结果进行了比较。体外对细胞抑制剂抑制作用较小的肿瘤细胞(阿霉素浓度为10⁻²mg/ml时抑制率小于30%)来自对细胞抑制疗法反应较差的患者。另一方面,体外受到强烈抑制的肿瘤细胞(抑制率大于30%)来自对给予患者的化疗敏感的肿瘤。即使在未使用阿霉素的联合治疗中,阿霉素体外抑制肿瘤细胞掺入尿苷的作用与肿瘤对临床治疗的反应之间也存在很强的相关性。阿霉素的体外抑制作用与肿瘤患者的生存时间之间也存在显著相关性。